Chemoprevention of biliary carcinogenesis in syrian hamsters by the novel carboxamide derivative IS-741 after initiation with N-nitrosobis(2-oxopropyl)amine (BOP).
To elucidate the possible inhibitory effect of a novel carboxamide derivative (IS-741) on biliary carcinogenesis, Syrian hamsters were subjected to cholecystoduodenostomy and ligation of the distal end of the common duct, and then given a regular diet (group I) or a diet containing 200 p.p.m. of IS-741 (group II). All hamsters were subcutaneously injected with N-nitrosobis(2-oxopropyl)amine until 10 weeks after surgery, and continued to feed on their respective dietary regimen until termination of the experiment at 16 weeks after surgery. Biliary adenocarcinomas were evaluated histologically. Non-cancerous and cancerous hepatobiliary tract tissues were analyzed for phospholipase A(2) (PLA(2)) activity, myeloperoxidase (MPO) activity, and the concentrations of prostaglandin (PG), i.e., prostaglandin E(2), 6-ketoprostaglandin F(1)alpha and thromboxane B(2). IS-741 significantly inhibited the development and multiplicity of hepatobiliary adenocarcinomas and reduced the proliferating cell nuclear antigen labeling indices in non-cancerous hepatobiliary tissues, compared with group I. The anti-cancerous effect of IS-741 was associated with a significant inhibition of PLA(2) and MPO levels in non-cancerous tissues of the extrahepatic biliary tract and the liver, and in cancerous tissue of the liver. Furthermore, IS-741 reduced the production of PGs in non-cancerous hepatobiliary tissues, compared with group I. Although the precise mechanism of action of IS-741 in preventing biliary tumorigenesis remains to be elucidated, it is likely to be related to modulation of arachidonic acid metabolism and/or suppression of neutrophil accumulation.
Ogura
Y
Y
Department of Surgery, National Mie Chuo Hospital, 2158-5 Myojin, Hisai City, 514-1101, Japan. yogura@alles.or.jp
Matsuda
S
S
Ito
M
M
Niimi
R
R
Sumitomo
M
M
Kawarada
Y
Y
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000230:Adenocarcinoma / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001659:Biliary Tract / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D001661:Biliary Tract Neoplasms / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D002273:Carcinogens; D002768:Choledochostomy; D003135:Common Bile Duct / Q000601:surgery; D006224:Cricetinae; D015232:Dinoprostone / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008647:Mesocricetus; D020556:Neutrophil Infiltration / Q000187:drug effects; D009602:Nitrosamines; D009195:Peroxidase / Q000378:metabolism; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011725:Pyridines / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000378:metabolism
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D004791:Enzyme Inhibitors; D009602:Nitrosamines; D018809:Proliferating Cell Nuclear Antigen; D011725:Pyridines; C097462:IS 741; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C013622:nitrosobis(2-oxopropyl)amine; D009195:Peroxidase; D010741:Phospholipases A; D015232:Dinoprostone